Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few studies evaluated the effectiveness and safety of apixaban according to its dosage, and most studies contained limited numbers...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyan, Keshishian, Allison, Hamilton, Melissa, Horblyuk, Ruslan, Gupta, Kiran, Luo, Xuemei, Mardekian, Jack, Friend, Keith, Nadkarni, Anagha, Pan, Xianying, Lip, Gregory Y. H., Deitelzweig, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786316/
https://www.ncbi.nlm.nih.gov/pubmed/29373602
http://dx.doi.org/10.1371/journal.pone.0191722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786316/
https://www.ncbi.nlm.nih.gov/pubmed/29373602
http://dx.doi.org/10.1371/journal.pone.0191722

Ejemplares similares